Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The status of targeted genes and the association between targeted genes and clinicopathological features in Chinese lung cancer patients remains to be elucidated.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The status of 10 targeted genes was evaluated by next‐generation sequencing (NGS) in 884 non‐small cell lung cancer (NSCLC) patients. The relationship between gene alterations and clinicopathological characters was analyzed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Overall, 684 (77.4%) patients harbored gene alterations, and <i>EGFR </i> (510, 57.7%) was found to be the most common type of mutation followed by <i>KRAS </i> (91, 10.3%), <i>HER2 </i> (38, 4.3%), <i>PIK3CA </i> (32, 3.6%), <i>ALK </i> (21, 2.4%), <i>BRAF </i> (10, 1.1%), <i>ROS1 </i> (5, 0.6%), <i>RET </i> (5, 0.6%), <i>MET </i> (4, 0.5%) and <i>NRAS </i> (1, 0.1%) Gene alterations were more frequent in females, non‐smokers and adenocarcinoma (<i>P </i> < 0.001). <i>EGFR </i> mutations were associated with women, non‐smokers, normal level of serum tumor markers, and adenocarcinoma <i>(P </i> < 0.001). Patients without lymph node metastasis (<i>P </i> = 0.012), or early stage disease (<i>P </i> < 0.001) exhibited a higher <i>EGFR </i> mutation rate. <i>KRAS </i> mutations tended to arise in men (<i>P </i> < 0.001), smokers (<i>P </i> < 0.001) and patients with higher levels of serum tumor markers (<i>P </i> = 0.048). A mucus‐producing component was associated with <i>KRAS </i> (<i>P </i> < 0.001), <i>ROS1 </i> (<i>P </i> = 0.033) and <i>ALK </i> (<i>P </i> < 0.001) alterations. <i>ALK </i> and <i>ROS1 </i> rearrangements were more frequent in micropapillary structures (<i>P </i> = 0.004, <i>P </i> = 0.012). <i>BRAF </i> mutation was associated with advanced disease patients and micropapillary structure (<i>P </i> < 0.001). <i>PIK3CA </i> mutation was more likely to be found in elderly patients (<i>P </i> = 0.014). Some patients had synchronous gene alterations, including <i>EGFR/PIK3CA </i>, <i>EGFR/HER2 </i>, <i>HER2/KRAS </i>, <i>EGFR/KRAS </i>, <i>EGFR/ROS1 </i>, <i>EGFR/NRAS </i>, <i>KRAS/PIK3CA </i>, <i>KRAS/PIK3CA/HER2. </i></p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Most patients had at least one genetic alteration, and individual patients harbored synchronous mutation. Each gene alteration had unique clinicopathological characteristics.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significant findings of the study</h3><p>This study revealed the frequency and distribution of 10 targeted gene abnormalities and their association with clinicopathological parameters of Chinese non‐small cell lung cancer (NSCLC) patients in eastern China.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> What this study adds</h3><p>Some rare synchronous mutations were detected in our study by next‐generation sequencing (NGS).</p></section>

Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer

The Genomic Profiling in Chinese Head and Neck Cancer and Incidence of NTRK Fusion

Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China

China Special Issue on Gastrointestinal Tumors—ntrk Fusion in a Large Real‐world Population and Clinical Utility of Circulating Tumor DNA Genotyping to Guide TRK Inhibitor Treatment

P2.03-09 the Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.

P1.03-23 the Molecular Landscape and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NTRK1 Point Mutations: A Retrospective Study

Large-Scale Study Of Ntrk Fusions In Chinese Solid Tumors And Using Next Generation Sequencing: A Multicenter Study

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

Expert Consensus on the Diagnosis and Treatment of NTRK Gene Fusion Solid Tumors in China

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

NTRK -rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China

Profiling receptor tyrosine kinase fusions in Chinese breast cancers.

Prognostic value and characterization of NTRK1 variation by fluorescence in situ hybridization in esophageal squamous cell carcinoma

Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.

Analysis of genomic alterations in pan-cancer from a large real-world Chinese population.

The clinical significance of RET gene fusion among Chinese patients with lung cancer

Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution

Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib